Tesaglitazar ameliorates non-alcoholic fatty liver disease and atherosclerosis development in diabetic low-density lipoprotein receptor-deficient mice

Experimental and Therapeutic Medicine

Volumn 4, Issue 6, 2012, Pages 987-992

  Zhang, Bu Chun ^a   Li, Wei Ming ^a   Li, Xian Kai ^a   Zhu, Meng Yun ^a   Che, Wen Liang ^a   Xu, Ya Wei ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Atherosclerosis; Inflammation; Mice; Non alcoholic fatty liver disease; Peroxisome proliferator activated receptor; Type 2 diabetes

Indexed keywords

AUTACOID; GLUCOSE; LIPID; LOW DENSITY LIPOPROTEIN RECEPTOR; TESAGLITAZAR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; FEMALE; INFLAMMATION; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; TREATMENT OUTCOME;

EID: 84867249671     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2012.713     Document Type: Article

References (24)

1. Menghini R, Casagrande V, Menini S, et al: TIMP3 over- expression in macrophages protects from insulin resistance, adipose inflammation, and nonalcoholic fatty liver disease in mice. Diabetes 61: 454-462, 2012.
2. Scorletti E, Calder PC, Byrne CD, et al: Non-alcoholic fatty liver disease and cardiovascular risk: metabolic aspects and novel treatments. Endocrine 40: 332-343, 2011.
3. Baeck C, Wehr A, Karlmark KR, et al: Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury. Gut 61: 416-426, 2012.
4. Serino M, Menghini R, Fiorentino L, et al: Mice heterozygous for tumor necrosis factor-alpha converting enzyme are protected from obesity-induced insulin resistance and diabetes. Diabetes 56: 2541-2546, 2007.
5. Wunderlich FT, Ströhle P, Könner AC, et al: Interleukin-6 signaling in liver-parenchymal cells suppresses hepatic inflam-mation and improves systemic insulin action. Cell Metab 12: 237-249, 2010.
6. Hanley AJ, Williams K, Festa A, et al: Liver markers and development of the metabolic syndrome: the insulin resistance atherosclerosis study. Diabetes 54: 3140-3147, 2005.
7. Bieghs V, Rensen PC, Hofker MH and Shiri-Sverdlov R: NASH and atherosclerosis are two aspects of a shared disease: central role for macrophages. Atherosclerosis 220: 287-293, 2012.
8. Gui T, Shimokado A, Sun Y, et al: Diverse roles of macrophages in atherosclerosis: from inflammatory biology to biomarker discovery. Mediators Inflamm 2012: 693083, 2012.
9. Truman JP, Al Gadban MM, Smith KJ, et al: Differential regulation of acid sphingomyelinase in macrophages stimulated with oxidized low-density lipoprotein (LDL) and oxidized LDL immune complexes: role in phagocytosis and cytokine release. Immunology 136: 30-45, 2012.
10. Wouters K, van Gorp PJ, Bieghs V, et al: Dietary cholesterol, rather than liver steatosis, leads to hepatic inflammation in hyperlipidemic mouse models of nonalcoholic steatohepatitis. Hepatology 48: 474-486, 2008.
11. Evans JL, Lin JJ and Goldfine ID: Novel approach to treat insulin resistance, type 2 diabetes, and the metabolic syndrome: simultaneous activation of PPARalpha, PPARgamma, and PPARdelta. Curr Diabetes Rev 1: 299-307, 2005.
12. Zandbergen F, Plutzky J: PPARalpha in atherosclerosis and inflammation. Biochim Biophys Acta 1771: 972-982, 2007.
13. Ciudin A, Hernandez C and Simó R: Update on cardiovascular safety of PPARgamma agonists and relevance to medicinal chemistry and clinical pharmacology. Curr Top Med Chem 12: 585-604, 2012.
14. Mu J, Woods J, Zhou YP, et al: Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. Diabetes 55: 1695-1704, 2006.
15. Zadelaar AS, Boesten LS, Jukema JW, et al: Dual PPARalpha/ gamma agonist tesaglitazar reduces atherosclerosis in insulin-resistant and hypercholesterolemic ApoE*3Leiden mice. Arterioscler Thromb Vasc Biol 26: 2560-2566, 2006.
16. Chira EC, McMillen TS, Wang S, et al: Tesaglitazar, a dual peroxisome proliferator-activated receptor alpha/gamma agonist, reduces atherosclerosis in female low density lipoprotein receptor deficient mice. Atherosclerosis 195: 100-109, 2007.
17. Ma KL, Ruan XZ, Powis SH, et al: Inflammatory stress exacerbates lipid accumulation in hepatic cells and fatty livers of apolipoprotein E knockout mice. Hepatology 48: 770-781, 2008.
18. Woollard KJ and Geissmann F: Monocytes in atherosclerosis: subsets and functions. Nat Rev Cardiol 7: 77-86, 2010.
19. Targher G, Marra F and Marchesini G: Increased risk of cardio-vascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon? Diabetologia 51: 1947-1953, 2008.
20. Bhatia LS, Curzen NP, Calder PC and Byrne CD: Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor? Eur Heart J 33: 1190-1200, 2012.
21. Kleemann R, Verschuren L, van Erk MJ, et al: Atherosclerosis and liver inflammation induced by increased dietary cholesterol intake: a combined transcriptomics and metabolomics analysis. Genome Biol 8: R200, 2007.
22. Maina V, Sutti S, Locatelli I, et al: Bias in macrophage activation pattern influences non-alcoholic steatohepatitis (NASH) in mice. Clin Sci (Lond) 122: 545-553, 2012.
23. Lingrel JB, Pilcher-Roberts R, Basford JE, et al: Myeloid-specific Krüppel-like factor 2 inactivation increases macrophage and neutrophil adhesion and promotes atherosclerosis. Circ Res 110: 1294-1302, 2012.
24. Amar J, Fauvel J, Drouet L, et al: Interleukin 6 is associated with subclinical atherosclerosis: a link with soluble intercellular adhesion molecule 1. J Hypertens 24: 1083-1088, 2006.